166 related articles for article (PubMed ID: 34462944)
1. Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact.
Krzisch D; Guedes N; Boccon-Gibod C; Baron M; Bravetti C; Davi F; Armand M; Smagghe L; Caron J; Bernard OA; Susin S; Chapiro E; Leblond V; Nguyen-Khac F; Roos-Weil D;
Am J Hematol; 2021 Dec; 96(12):1569-1579. PubMed ID: 34462944
[TBL] [Abstract][Full Text] [Related]
2.
Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
[No Abstract] [Full Text] [Related]
3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Nguyen-Khac F; Lambert J; Chapiro E; Grelier A; Mould S; Barin C; Daudignon A; Gachard N; Struski S; Henry C; Penther D; Mossafa H; Andrieux J; Eclache V; Bilhou-Nabera C; Luquet I; Terre C; Baranger L; Mugneret F; Chiesa J; Mozziconacci MJ; Callet-Bauchu E; Veronese L; Blons H; Owen R; Lejeune J; Chevret S; Merle-Beral H; Leblondon V; ; ;
Haematologica; 2013 Apr; 98(4):649-54. PubMed ID: 23065509
[TBL] [Abstract][Full Text] [Related]
5. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
[TBL] [Abstract][Full Text] [Related]
6. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
[TBL] [Abstract][Full Text] [Related]
7. Clonal chromosome abnormalities in patients with Waldenström's and CLL-associated macroglobulinemia: significance of trisomy 12.
Han T; Sadamori N; Takeuchi J; Ozer H; Henderson ES; Bhargava A; Fitzpatrick J; Sandberg AA
Blood; 1983 Sep; 62(3):525-31. PubMed ID: 6411149
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.
Chang H; Qi C; Trieu Y; Jiang A; Young KH; Chesney A; Jani P; Wang C; Reece D; Chen C
Clin Lymphoma Myeloma; 2009 Mar; 9(1):36-8. PubMed ID: 19362968
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma.
Ocio EM; Hernandez JM; Mateo G; Sanchez ML; Gonzalez B; Vidriales B; Gutierrez NC; Orfao A; San Miguel JF
Clin Lymphoma; 2005 Mar; 5(4):241-5. PubMed ID: 15794856
[TBL] [Abstract][Full Text] [Related]
10. Isochromosome (6p) in Waldenstrom's macroglobulinemia.
White AD; Clark RE; Jacobs A
Cancer Genet Cytogenet; 1992 Jan; 58(1):89-91. PubMed ID: 1728957
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
12. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
13. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
[No Abstract] [Full Text] [Related]
15. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.
Garcia-Sanz R; Varettoni M; Jiménez C; Ferrero S; Poulain S; San-Miguel JF; Guerrera ML; Drandi D; Bagratuni T; McMaster M; Roccaro AM; Roos-Weil D; Leiba M; Li Y; Qiu L; Hou J; De Larrea CF; Castillo JJ; Dimopoulos M; Owen RG; Treon SP; Hunter ZR
Semin Hematol; 2023 Mar; 60(2):90-96. PubMed ID: 37099028
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course.
Mansoor A; Medeiros LJ; Weber DM; Alexanian R; Hayes K; Jones D; Lai R; Glassman A; Bueso-Ramos CE
Am J Clin Pathol; 2001 Oct; 116(4):543-9. PubMed ID: 11601139
[TBL] [Abstract][Full Text] [Related]
17. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.
Landgren O; Tageja N
Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
[TBL] [Abstract][Full Text] [Related]
19. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.
Ocio EM; Schop RF; Gonzalez B; Van Wier SA; Hernandez-Rivas JM; Gutierrez NC; Garcia-Sanz R; Moro MJ; Aguilera C; Hernandez J; Xu R; Greipp PR; Dispenzieri A; Jalal SM; Lacy MQ; Gonzalez-Paz N; Gertz MA; San Miguel JF; Fonseca R
Br J Haematol; 2007 Jan; 136(1):80-6. PubMed ID: 17222197
[TBL] [Abstract][Full Text] [Related]
20. Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia.
Bang SM; Seo JW; Park KU; Kim SJ; Kim K; Kim SH; Cho SR; Kim HC; Song J; Kim JS; Kim KH; Lee JH; Lee JJ; Shin MG; Suh C; Chi HS; Oh DY; Won JH; Kim HJ; Yoon SS; Lee DS;
Cancer Genet Cytogenet; 2010 Mar; 197(2):117-21. PubMed ID: 20193844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
